SEC Form SC 13D/A filed by Genesco Inc. (Amendment)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 15)¹

Genesco Inc.

(Name of Issuer)

Common Stock, $1.00 par value per share

(Title of Class of Securities)

371532102

(CUSIP Number)

CHRISTOPHER S. KIPER

LEGION PARTNERS ASSET MANAGEMENT, LLC

12121 Wilshire Blvd, Suite 1240

Los Angeles, California 90025

(424) 253-1773

ELIZABETH GONZALEZ-SUSSMAN, ESQ.

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

January 20, 2023

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The following constitutes Amendment No. 15 to the Schedule 13D filed by the undersigned (“Amendment No. 15”). This Amendment No. 15 amends the Schedule 13D as specifically set forth herein.

Item 3 is hereby amended and restated to read as follows:

The aggregate purchase price of the 671,120 Shares owned directly by Legion Partners I is approximately $28,402,191, including brokerage commissions. The aggregate purchase price of the 56,822 Shares owned directly by Legion Partners II is approximately $2,363,112, including brokerage commissions. The aggregate purchase price of the 100 Shares owned directly by Legion Partners Holdings is approximately $3,612, including brokerage commissions.

Item 5(a)-(c) is hereby amended and restated to read as follows:

The aggregate percentage of Shares reported owned by each person named herein is based upon 12,609,875 Shares outstanding as of November 25, 2022, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on December 8, 2022.

Percentage: 5.3%

Percentage: Less than 1%

Percentage: 5.8%

Percentage: 5.8%

Percentage: 5.8%

Percentage: 5.8%

Item 6 is hereby amended to add the following:

Legion Partners I previously sold short in the over-the-counter market American-style call options referencing an aggregate of 285,000 Shares, which had an exercise price of $45 per Share and expiring on January 20, 2023. Legion Partners I has subsequently purchased these call options prior to the expiration date to cover its short position, as set forth on Schedule A, which is incorporated herein by reference. Accordingly, Legion Partners I no longer has any exposure to such call options.

Legion Partners II previously sold short in the over-the-counter market American-style call options referencing an aggregate of 24,100 Shares, which had an exercise price of $45 per Share and expiring on January 20, 2023. Legion Partners II has subsequently purchased these call options prior to the expiration date to cover its short position, as set forth on Schedule A, which is incorporated herein by reference. Accordingly, Legion Partners II no longer has any exposure to such call options.

Each of Legion Partners I and Legion Partners II previously sold short in the over-the-counter market American-style call options referencing an aggregate of 92,200 Shares and 7,800 Shares, respectively, which had an exercise price of $50 per Share. These call options expired worthless pursuant to their terms on January 20, 2023. Accordingly, none of Legion Partners I or Legion Partners II has any exposure to such call options.

Each of Legion Partners I and Legion Partners II previously sold short in the over-the-counter market American-style call options referencing an aggregate of 50,700 Shares and 4,300 Shares, respectively, which had an exercise price of $55 per Share. These call options expired worthless pursuant to their terms on January 20, 2023. Accordingly, none of Legion Partners I or Legion Partners II has any exposure to such call options.

Legion Partners I previously sold short in the over-the-counter market American-style call options referencing an aggregate of 184,400 Shares, with an exercise price of $40 per Share and expiring on January 20, 2023. At expiration, call options referencing 184,400 Shares were assigned, resulting in the sale of stock, as set forth on Schedule A, which is incorporated herein by reference.

Legion Partners II previously sold short in the over-the-counter market American-style call options referencing an aggregate of 15,600 Shares, with an exercise price of $40 per Share and expiring on January 20, 2023. At expiration, call options referencing 15,600 Shares were assigned, resulting in the sale of stock, as set forth on Schedule A, which is incorporated herein by reference.

Legion Partners I has sold short in the over-the-counter market American-style call options referencing an aggregate of 285,000 Shares, which have an exercise price of $45 per Share and expire on February 17, 2023, as set forth on Schedule A, which is incorporated herein by reference.

Legion Partners II has sold short in the over-the-counter market American-style call options referencing an aggregate of 24,100 Shares, which have an exercise price of $45 per Share and expire on February 17, 2023, as set forth on Schedule A, which is incorporated herein by reference.

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 24, 2023

SCHEDULE A

Transactions in the Securities of the Issuer Since the Filing of Amendment No. 14 to the Schedule 13D

LEGION PARTNERS, L.P. I

LEGION PARTNERS, L.P. II

______________________________________

¹ Represents shares underlying American-style call options sold short in the over-the-counter market with an expiration date of January 20, 2023, all of which were covered.

² Represents shares underlying American-style call options purchased to close a short position in the over-the-counter market with an expiration date of January 20, 2023.

³ Represents shares underlying American-style call options sold short in the over-the-counter market with an expiration date of February 17, 2023.

⁴ Represents Shares disposed of in connection with the assignment of certain American-style call options that were sold short in the over-the-counter market.